69 Results for "

abl tyrosine kinase

" in MedChemExpress (MCE) Product Catalog:
Products (69)

69 Results for "abl tyrosine kinase" in MCE Product Catalog:

131
131 Publications Verification
Cat. No.: HY-15463
CAS No.: 152459-95-5
Purity:  99.95%
Synonyms: STI571; CGP-57148B
Research Areas:  

Cancer

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
loading...
    loading...
131
131 Publications Verification
Cat. No.: HY-50946
CAS No.: 220127-57-1
Synonyms: STI571 Mesylate; CGP-57148B Mesylate
Imatinib Mesylate (STI571 Mesylate) is an orally active tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.
loading...
    loading...
53
53 Cited Publications
Cat. No.: HY-10159
CAS No.: 641571-10-0
Purity:  99.94%
Synonyms: AMN107
Target:  

Bcr-Abl Autophagy

Research Areas:  

Cancer

Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
loading...
    loading...
53
53 Cited Publications
Cat. No.: HY-10159A
CAS No.: 923288-90-8
Purity:  99.91%
Synonyms: AMN107 monohydrochloride monohydrate
Target:  

Bcr-Abl Autophagy

Research Areas:  

Cancer

Nilotinib monohydrochloride monohydrate is a second generation tyrosine kinase inhibitor (TKI), is significantly potent against BCR-ABL, and is active against many BCR-ABL mutants.
loading...
    loading...
53
53 Cited Publications
Cat. No.: HY-10159C
Synonyms: AMN107 hydrochloride dihydrate
Target:  

Autophagy Bcr-Abl

Research Areas:  

Cancer

Nilotinib (AMN107) hydrochloride dihydrate is an orally active Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity and can be used in studies of chronic myelogenous leukaemia .
loading...
    loading...
53
53 Cited Publications
Cat. No.: HY-10159B
CAS No.: 923288-95-3
Synonyms: AMN107 hydrochloride
Target:  

Bcr-Abl Autophagy

Research Areas:  

Cancer

Nilotinib (AMN107) hydrochloride is an orally active Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity and can be used in studies of chronic myelogenous leukaemia .
loading...
    loading...
26
26 Cited Publications
Cat. No.: HY-10158
CAS No.: 380843-75-4
Purity:  99.89%
Synonyms: SKI-606
Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC50 of 1.2 nM and 1 nM, respectively .
loading...
    loading...
26
26 Cited Publications
Cat. No.: HY-10158A
CAS No.: 918639-08-4
Purity:  99.97%
Synonyms: SKI-606 hydrate
Target:  

Src Bcr-Abl

Research Areas:  

Cancer

Bosutinib hydrate is an oraly activel Src/Abl tyrosine kinase inhibito with IC50 of 1.2 nM and 1 nM, respectively .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-50868
CAS No.: 859212-16-1
Synonyms: INNO-406; NS-187
Target:  

Bcr-Abl Src Apoptosis

Research Areas:  

Cancer

Bafetinib is an orally active Lyn/Bcr-Abl tyrosine kinase inhibitor. Bafetinib enhances the activity of several pro-apoptotic Bcl-2 homology (BH) 3-pure proteins (Bim, Bad, Bmf, and Bik) through intrinsic apoptotic pathways regulated by the Bcl-2 family, and induces apoptosis of Ph + leukemia cells. Bafetinib has antitumor activity .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-15749
CAS No.: 898280-07-4
Purity:  99.64%
Research Areas:  

Endocrinology Cancer

XL228 is a multi-targeted tyrosine kinase inhibitor with IC50s of 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src and Lyn, respectively.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-137460
CAS No.: 1388803-90-4
Purity:  99.85%
Synonyms: K0706
Target:  

Bcr-Abl

Research Areas:  

Cancer

Vodobatinib (K0706) is a potent, third generation and orally active Bcr-Abl1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants, and has no activity against BCR-ABL1T315I. Vodobatinib can be used for chronic myeloid leukemia (CML) research . Vodobatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-15728
CAS No.: 926037-48-1
Purity:  98.92%
Synonyms: IY-5511
Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-122113
CAS No.: 305820-75-1
Purity:  99.44%
Target:  

Src Bcr-Abl Apoptosis Wee1

Research Areas:  

Cancer

PD173952 is a tyrosine kinases inhibitor with IC50s of 0.3, 1.7 and 6.6 nM against Lyn, Abl and Csk, respectively. PD173952 is also a potent Myt1 kinase inhibitor with a Ki of 8.1 nM. PD173952 induces apoptosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-10181S
CAS No.: 1132093-70-9
Purity:  98.17%
Synonyms: BMS-354825-d8
Dasatinib-d8 (BMS-354825-d8) is a deuterium labeled Dasatinib. Dasatinib is a dual Bcr-Abl and Src family tyrosine kinase inhibitor.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-15463S
CAS No.: 1092942-82-9
Purity:  99.85%
Synonyms: STI571-d8; CGP-57148B-d8
Imatinib-d8 is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .
loading...
    loading...
Cat. No.: HY-147414
CAS No.: 1416241-23-0
Purity:  98.69%
Synonyms: PF-114
Target:  

Bcr-Abl

Research Areas:  

Cancer

Vamotinib (PF-114) is a potent, selective and orally active tyrosine kinase inhibitor. Vamotinib inhibits the autophosphorylation of BCR/ABL and BCR/ABL-T315I. Vamotinib induces apoptosis. Vamotinib shows anti-proliferative and anti-tumor activity. Vamotinib has the potential for the research of resistant philadelphia chromosome-positive (Ph+) leukemia. Vamotinib inhibits ABL series kinases with IC50s of 0.49 nM (ABL), 0.78 nM (ABL T315I), 9.5 nM (ABL E255K), 2.0 nM (ABL F317I), 7.4 nM (ABL G250E), 1.0 nM (ABL H396P), 2.8 nM (ABL M351T), 12 nM (ABL Q252H), and 4.1 nM (ABL Y253F), respectively . Vamotinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-148794
CAS No.: 2031185-00-7
Purity:  98.42%
Synonyms: IkT-148009
Target:  

c-Met/HGFR Bcr-Abl

Research Areas:  

Neurological Disease Cancer

Risvodetinib (IkT-148009) is an orally active, selective and brain-penetrant protein tyrosine kinase inhibitor, displaying excellent target efficacy against c-Abl1, c-Abl2/Arg with IC50 values of 33 nM, 14 nM, respectively. Risvodetinib suppresses c-Abl activation and substantially protects dopaminergic neurons from degeneration in mouse models of both inherited and sporadic Parkinson’s disease (PD), which is promising for research in the field of PD .
loading...
    loading...
Cat. No.: HY-118144
CAS No.: 185039-91-2
Purity:  99.99%
Target:  

Src Bcr-Abl p38 MAPK

Research Areas:  

Cancer

PD166326 is an orally active tyrosine kinase inhibitor with a IC50 of 8 nM against abl tyrosine kinase and a IC50 of 6 nM against src tyrosine kinase. PD166326 blocks Bcr/Abl kinase activity. PD166326 inhibits Bcr/Abl-dependent proliferation and cell cycle progression. PD166326 reduces peripheral blood granulocytosis, alleviates splenomegaly and prolongs survival in a mouse model of chronic myeloid leukemia. PD166326 can be used in research related to chronic myeloid leukemia .
loading...
    loading...
Cat. No.: HY-15463S1
CAS No.: 1134803-16-9
Purity:  99.97%
Synonyms: STI571 d4; CGP-57148B d4
Imatinib-d4 (STI571-d4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .
loading...
    loading...
Cat. No.: HY-103032
CAS No.: 778274-97-8
Purity:  99.34%
Target:  

PDGFR c-Kit Bcr-Abl

Research Areas:  

Cancer

Multi-kinase inhibitor 1 is a potent multi-kinase inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl .
loading...
    loading...